Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor plus ticagrelor versus ticagrelor alone in STEMI patients undergoing primary PCI
2016-002586-64Phase 3Completed
- Sponsor
- ELKE NKUA
- Start
- Sep 2016
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myocardial infarction (MI) comparing Ticagrelor plus cangrelor with Ticagrelor alone (2 arms). Primary endpoint: Platelet reactivity at 15 minutes. Started Sep 2016; status: completed.
02
Drugs
cangrelorticagrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2016-002586-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002586-64.